Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
Department of Laboratory Medicine, Lithuanian University of Health Science, 44307 Kaunas, Lithuania.
Int J Infect Dis. 2020 Apr;93:268-276. doi: 10.1016/j.ijid.2020.02.018. Epub 2020 Feb 17.
Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral families) could provide additional protection of the general population from emerging and re-emerging viral diseases, reinforcing the arsenal of available antiviral options. Here, we review discovery and development of BSAAs and summarize the information on 120 safe-in-man agents in a freely accessible database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand the spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging viral infections as well as co-infections.
病毒性疾病是世界范围内发病率和死亡率的主要原因之一。病毒特异性疫苗和抗病毒药物是对抗病毒性疾病最有力的工具。然而，广谱抗病毒药物（BSAA，即针对属于两个或多个病毒科的病毒的化合物）可以为普通人群提供额外的保护，使其免受新发和再发病毒性疾病的影响，从而增强现有的抗病毒药物选择。在这里，我们回顾了广谱抗病毒药物的发现和开发，并在一个可免费获取的数据库（https://drugvirus.info/）中总结了 120 种已在人体中安全使用的药物信息。未来和正在进行的临床前和临床研究将增加广谱抗病毒药物的数量，扩大其适应症范围，并确定用于治疗新发和再发病毒感染以及合并感染的药物组合。
